Citigroup Inc Acumen Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 30,592 shares of ABOS stock, worth $60,266. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,592

Previous 9,415 224.93%

Holding current value

$60,266

Previous $22,000 240.91%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.22 - $3.54 $47,012 - $74,966	21,177 Added 224.93%	30,592 $75,000
Q2 2024 Aug 12, 2024	SELL	$2.14 - $4.01 $269,595 - $505,175	-125,979 Reduced 93.05%	9,415 $22,000
Q1 2024 May 10, 2024	SELL	$2.97 - $4.64 $36,878 - $57,614	-12,417 Reduced 8.4%	135,394 $548,000
Q4 2023 Feb 09, 2024	BUY	$1.86 - $4.48 $203,322 - $489,722	109,313 Added 283.94%	147,811 $567,000
Q3 2023 Nov 09, 2023	BUY	$4.15 - $9.72 $156,874 - $367,425	37,801 Added 5423.39%	38,498 $159,000
Q2 2023 Aug 10, 2023	SELL	$3.59 - $6.59 $146,041 - $268,081	-40,680 Reduced 98.32%	697 $3,000
Q1 2023 May 11, 2023	SELL	$3.75 - $6.65 $15,738 - $27,910	-4,197 Reduced 9.21%	41,377 $167,000
Q4 2022 Feb 09, 2023	BUY	$4.81 - $10.17 $179,210 - $378,913	37,258 Added 448.03%	45,574 $246,000
Q3 2022 Nov 10, 2022	BUY	$4.44 - $10.48 $32,789 - $77,394	7,385 Added 793.23%	8,316 $83,000
Q2 2022 Aug 10, 2022	SELL	$3.08 - $4.88 $8,506 - $13,478	-2,762 Reduced 74.79%	931 $4,000
Q1 2022 May 12, 2022	SELL	$3.91 - $6.73 $774 - $1,332	-198 Reduced 5.09%	3,693 $14,000
Q4 2021 Feb 10, 2022	BUY	$6.54 - $15.31 $18,292 - $42,822	2,797 Added 255.67%	3,891 $26,000
Q3 2021 Nov 10, 2021	BUY	$14.5 - $20.28 $15,863 - $22,186	1,094 New	1,094 $16,000

Others Institutions Holding ABOS

# of Institutions

Shares Held

41.8M

Call Options Held

57.7K

Put Options Held

749K

View Full List

About Acumen Pharmaceuticals, Inc.

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $79.8M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

More about ABOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account